|
1
|
Soda M, Takada S, Takeuchi K, Choi YL,
Enomoto M, Ueno T, Haruta H, Hamada T, Yamashita Y, Ishikawa Y, et
al: A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad
Sci USA. 105:19893–19897. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li T, Maus MK, Desai SJ, Beckett LA,
Stephens C, Huang E, Hsiang J, Zeger G, Danenberg KD, Astrow SH and
Gandara DR: Large-scale screening and molecular characterization of
EML4-ALK fusion variants in archival non-small-cell lung cancer
tumor specimens using quantitative reverse transcription polymerase
chain reaction assays. J Thorac Oncol. 9:18–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Peters S, Camidge DR, Shaw AT, Gadgeel S,
Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, et al:
Alectinib versus crizotinib in untreated ALK-positive
non-small-cell lung cancer. N Engl J Med. 377:829–838. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Soria JC, Tan DSW, Chiari R, Wu YL,
Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, et al:
First-line ceritinib versus platinum-based chemotherapy in advanced
ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised,
open-label, phase 3 study. Lancet. 389:917–929. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim DW, Tiseo M, Ahn MJ, Reckamp KL,
Hansen KH, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, et
al: Brigatinib in patients with crizotinib-refractory anaplastic
lymphoma kinase-positive non-small-cell lung cancer: A randomized,
multicenter phase II trial. J Clin Oncol. 35:2490–2498. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shaw AT, Felip E, Bauer TM, Besse B,
Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James
LP, et al: Lorlatinib in non-small-cell lung cancer with ALK or
ROS1 rearrangement: An international, multicentre, open-label,
single-arm first-in-man phase 1 trial. Lancet Oncol. 18:1590–1599.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó
L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rangachari D, Le X, Shea M, Huberman MS,
VanderLaan PA, Kobayashi SS and Costa DB: Cases of ALK-rearranged
lung cancer with 5-year progression-free survival with crizotinib
as initial precision therapy. J Thorac Oncol. 12:e175–e177. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Horn L and Pao W: EML4-ALK: Honing in on a
new target in non-small-cell lung cancer. J Clin Oncol.
27:4232–4235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sasaki T, Rodig SJ, Chirieac LR and Jänne
PA: The biology and treatment of EML4-ALK non-small cell lung
cancer. Eur J Cancer. 46:1773–1780. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock
AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, et al:
Impact of EML4-ALK variant on resistance mechanisms and clinical
outcomes in ALK-positive lung cancer. J Clin Oncol. 36:1199–1206.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li Y, Zhang T, Zhang J, Li W, Yuan P, Xing
P, Zhang Z, Chuai S, Li J and Ying J: Response to crizotinib in
advanced ALK-rearranged non-small cell lung cancers with different
ALK-fusion variants. Lung Cancer. 118:128–133. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McLeer-Florin A, Duruisseaux M, Pinsolle
J, Dubourd S, Mondet J, Phillips Houlbracq M, Magnat N, Fauré J,
Chatagnon A, de Fraipont F, et al: ALK fusion variants detection by
targeted RNA-next generation sequencing and clinical responses to
crizotinib in ALK-positive non-small cell lung cancer. Lung Cancer.
116:15–24. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Woo CG, Seo S, Kim SW, Jang SJ, Park KS,
Song JY, Lee B, Richards MW, Bayliss R, Lee DH and Choi J:
Differential protein stability and clinical responses of EML4-ALK
fusion variants to various ALK inhibitors in advanced
ALK-rearranged non-small cell lung cancer. Ann Oncol. 28:791–797.
2017.PubMed/NCBI
|
|
16
|
Yoshida T, Oya Y, Tanaka K, Shimizu J,
Horio Y, Kuroda H, Sakao Y, Hida T and Yatabe Y: Differential
crizotinib response duration among ALK fusion variants in
ALK-positive non-small-cell lung cancer. J Clin Oncol.
34:3383–3389. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cha YJ, Kim HR and Shim HS: Clinical
outcomes in ALK-rearranged lung adenocarcinomas according to ALK
fusion variants. J Transl Med. 14:2962016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lei YY, Yang JJ, Zhang XC, Zhong WZ, Zhou
Q, Tu HY, Tian HX, Guo WB, Yang LL, Yan HH, et al: Anaplastic
lymphoma kinase variants and the percentage of ALK-positive tumor
cells and the efficacy of crizotinib in advanced NSCLC. Clin Lung
Cancer. 17:223–231. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Heuckmann JM, Balke-Want H, Malchers F,
Peifer M, Sos ML, Koker M, Meder L, Lovly CM, Heukamp LC, Pao W, et
al: Differential protein stability and ALK inhibitor sensitivity of
EML4-ALK fusion variants. Clin Cancer Res. 18:4682–4690. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin JJ, Cardarella S, Lydon CA, Dahlberg
SE, Jackman DM, Jänne PA and Johnson BE: Five-year survival in
EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs.
J Thorac Oncol. 11:556–565. 2016. View Article : Google Scholar : PubMed/NCBI
|
